Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9894102 | Prostaglandins & Other Lipid Mediators | 2005 | 4 Pages |
Abstract
A phase I study of fixed-dose 5-fluorouracil (FU) and leucovorin (LCV), with excalating doses of the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib, was conducted in 16 patients with advanced colorectal adenocarcinoma. At doses typically used to treat arthritis patients (100-200Â mg po BID), celecoxib did not increase toxicities expected from the chemotherapy alone. 5-FU and leucovorin did not affect COX-2 inhibition by celecoxib. Preliminary data suggest it is safe to combine celecoxib with standard chemotherapeutic agents, in treatment of patients with colorectal cancer.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Charles D. Blanke, Nora C. Mattek, Thomas G. Deloughery, Dennis R. Koop,